Welcome to our dedicated page for Bioventus news (Ticker: BVS), a resource for investors and traders seeking the latest updates and insights on Bioventus stock.
Bioventus Inc. (Nasdaq: BVS) is a medical technology company that describes itself as a global leader in innovations for active healing. The Bioventus news stream features company announcements, financial updates and product milestones that reflect its focus on Pain Treatments, Surgical Solutions and Restorative Therapies.
Investors following BVS news will find regular earnings releases where Bioventus reports net sales, segment performance across Pain Treatments, Surgical Solutions and Restorative Therapies, and metrics such as net income, Adjusted EBITDA and non-GAAP earnings. These updates often include commentary on organic revenue trends, portfolio changes like the divestiture of the Advanced Rehabilitation Business, and the impact of factors such as foreign currency and tariffs.
The company also issues product and regulatory news, including announcements of U.S. Food and Drug Administration (FDA) 510(k) clearances. Recent examples include clearances for TalisMann and StimTrial, two Peripheral Nerve Stimulation products for chronic pain management that Bioventus highlights as expanding its non-opioid, minimally invasive therapy portfolio.
Bioventus news items cover capital structure and financing developments, such as the entry into a new senior secured credit agreement that refinanced prior debt, increased revolving capacity and reduced interest margins. In addition, the company regularly announces participation in major healthcare and investor conferences hosted by firms such as J.P. Morgan, Piper Sandler, Morgan Stanley and Canaccord Genuity.
For readers tracking BVS, the news page provides a centralized view of Bioventus’ financial performance, product pipeline progress, regulatory milestones and corporate events, helping contextualize how its Pain Treatments, Surgical Solutions and Restorative Therapies businesses evolve over time.
Bioventus has appointed Larry Chen as Managing Director for China and Asia Pacific to enhance market penetration of its products. Chen, with over 20 years in healthcare sales and marketing, will focus on Bioventus' presence in China. His previous roles include key positions at Zipline Medical and Smith & Nephew. The company's mission centers on providing effective solutions for osteoarthritis and bone healing, benefiting both patients and clinicians.
Bioventus Inc. (Nasdaq: BVS) announced that it will release its fourth quarter and fiscal year 2020 financial results on March 25, 2021, after market close. Management will host a conference call at 5:00 p.m. ET on the same day to discuss the results and provide a business update, followed by a Q&A session. Interested participants can join via phone or through a live webcast available on the investor relations section of the company's website. The webcast will be archived for replay until March 25, 2022.
DURHAM, N.C., Feb. 10, 2021 - Bioventus has priced its initial public offering (IPO) of 8,000,000 shares of Class A common stock at $13.00 per share. The shares are expected to begin trading on Nasdaq under the symbol 'BVS', with the offering set to close on February 16, 2021. The gross proceeds from the offering are anticipated to be around $104 million, potentially increasing to $119.6 million if underwriters exercise their option for an additional 1,200,000 shares. Morgan Stanley, J.P. Morgan, and Goldman Sachs are the lead underwriters.
Bioventus has initiated its initial public offering (IPO) of 7,350,000 Class A common stock shares, pricing expected between $16.00 and $18.00 each. The underwriters may purchase an additional 1,102,500 shares for overallotments. The shares will trade on Nasdaq under the symbol 'BVS.' Morgan Stanley, J.P. Morgan, and Goldman Sachs are leading the offering, while a registration statement has been filed with the SEC but is not yet effective. This IPO aims to fund Bioventus' mission to provide clinically proven products that promote healing and enhance active lifestyles.